Zeposia — Total Revenues
Bristol-Myers Squibb Zeposia — Total Revenues decreased by 25.8% to $118M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.3%, from $107M to $118M. Over 4 years (FY 2021 to FY 2025), Zeposia — Total Revenues shows an upward trend with a 44.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market adoption and growth in the immunology therapeutic area, while a decrease may signal increased competition or loss of market share.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Zeposia, a sphingosine-1-phosp...
Peer comparison
Comparable to revenue metrics for specific specialty pharmaceutical products or key growth drivers in the immunology portfolios of major biopharmaceutical peers.
bmy_segment_zeposia_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28M | $40M | $48M | $36M | $66M | $69M | $79M | $78M | $100M | $123M | $133M | $110M | $151M | $147M | $158M | $107M | $150M | $161M | $159M | $118M |
| QoQ Change | — | +42.9% | +20.0% | -25.0% | +83.3% | +4.5% | +14.5% | -1.3% | +28.2% | +23.0% | +8.1% | -17.3% | +37.3% | -2.6% | +7.5% | -32.3% | +40.2% | +7.3% | -1.2% | -25.8% |
| YoY Change | — | — | — | — | +135.7% | +72.5% | +64.6% | +116.7% | +51.5% | +78.3% | +68.4% | +41.0% | +51.0% | +19.5% | +18.8% | -2.7% | -0.7% | +9.5% | +0.6% | +10.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's zeposia — total revenues?
- Bristol-Myers Squibb (BMY) reported zeposia — total revenues of $118M in Q1 2026.
- How has Bristol-Myers Squibb's zeposia — total revenues changed year-over-year?
- Bristol-Myers Squibb's zeposia — total revenues increased by 10.3% year-over-year, from $107M to $118M.
- What is the long-term trend for Bristol-Myers Squibb's zeposia — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's zeposia — total revenues has grown at a 44.1% compound annual growth rate (CAGR), from $134M to $577M.
- What does zeposia — total revenues mean?
- The total revenue generated from sales of the drug Zeposia.